

8. Literatur

1. Bernstein HN, Ginsberg J. The pathology of chloroquine retinopathy. *Arch Ophthalmol*, 1964. 71:238-245.
2. Bishara SA, Matamoros N. Evaluation of several tests in screening for chloroquine maculopathy. *Eye*, 1989. 3: 777-782.
3. Easterbrook M. Long-term course of antimalarial maculopathy after cessation of treatment. *Can J Ophthalmol*, 1992. 27: 237-239.
4. Fishman GA. Retinal toxicity with the use of chloroquine or hydroxychloroquine. In: Heckenlively JR, Arden GB, editors. *Principles and practice of clinical electrophysiology of vision*. St. Louis , Mosby, 1991, p. 594-599.
5. Kellner U, Kraus H, Foerster MH. Multifocal ERG in chloroquine retinopathy: regional variance of retinal dysfunction. *Graefe's Arch Clin Exp Ophthalmol*, 2000. 238: 94-97.
6. Rosenthal RA, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. *Invest Ophthalmol Vis Sci*, 1978. 17: 1158-1175.
7. Wetterholm DH, Winter FC. Histopathology of chloroquine retinal toxicity. *Arch Ophthalmol*, 1964. 71: 82-87.
8. Sutter EE, Tran D. The field topography of ERG components in man – I. The photopic luminance response. *Vision Res*, 1992. 32: 433-446.
9. Hood DC, Seiple W, Holopigian K, Greenstein V: A comparison of the components of the multifocal and full-field ERGs. *Visual Neurosci*, 1997. 14: 533-544.

10. Cambiaggi A: Unusual ocular lesions in a case of systemic lupus erythematosus. *Am J Ophthal*, 1957. 57: 451-453.
11. Hobbs HE, Sorsy A, Freedman A: Retinopathy following chloroquine therapy. *Lancet*, 1959. 2: 478-480.
12. Matsumura M, Ohkuma M, Tsukahara I: Experimental Chloroquine Retinopathy. *Ophthalmic Res*, 1986. 18: 172-179.
13. Abraham R, Hendy RJ: Irreversible lysosomal damage induced by chloroquine in the retina of pigmented and albino rats. *Expl Eye Res*, 1970. 12: 185-200.
14. Sassani JW, Brucker AJ, Cobbs W, Campbell C: Progressive chloroquine retinopathy. *Ann Ophthal*, 1983. 15: 19-22.
15. Rubin M, Bernstein H, Zvaifler N: Studies on the pharmacology of chloroquine with recommendations for the treatment of chloroquine retinopathy. *Arch Ophthal*, 1963. 70: 474-481.
16. Mamor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. *Ophthalmology*, 2002. 109(7): 1377-82.
17. Mackenzie AH: Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. *Am J Med*, 1983. 75: 40-45.
18. Levy GD, Munz SJ, Paschal J, et al: Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. *Arthritis Rheum*, 1997. 40: 1482-1486.
19. Mavrikakis M, Papazoglou S, Sfrikakis PP, et al: Retinal toxicity in long term hydroxychloroquine treatment. *Ann Rheum Dis*, 1996. 55: 187-189.

20. Finbloom DS, Silver K, Newsome DA, Gunkel R: Comparison of hydroxychloroquine and chloroquine use and the development of retinal toxicity. *J Rheumatol*, 1985. 12: 692-694.
21. Voipio H: Incidence of chloroquine retinopathy. *Acta Ophthalmol (Copenh)*, 1966. 44: 349-354.
22. Silman A, Shipley M: Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. *Br J Rheumatol*, 1997. 36: 599-601.
23. Nylander U: Ocular damage in chloroquine therapy. *Acta Ophthalmol (Copenh)*, 1966. 44: 335-348.
24. Johnson MW, Vine AK: Hydroxychloroquine therapy in massive total doses without retinal toxicity. *Am J Ophthalmol*, 1987. 104: 139-144.
25. Hallberg A, Naeser P, Andersson A: Effects of long-term chloroquine exposure on the phospholipid metabolism in retina and pigment epithelium of the mouse. *Acta Ophthalmol (Copenh)*, 1990. 68: 125-130.
26. Gonasun LM, Potts AM. In vitro inhibition of protein synthesis in the retinal pigment epithelium by chloroquine. *Invest Ophthalmol*, 1974. 13: 107-115.
27. Ivanina TA, Sakina NL, Lebedeva MN, Borovjagin VL: A study of the mechanisms of chloroquine retinopathy. II. Chloroquine effect on protein synthesis of retina, *Ophthalmic Res*, 1989. 21: 272-277.
28. Lachenmayr B, Vivell PMO: *Perimetrie*. Thieme Stuttgart –New Vork, 1992.
29. Marmor MF, Hood DC, Keating D, Kondo M, Seeliger MW, Miyake Y (for the International Society for Clinical Electrophysiology of Vision): Guidelines for basic multifocal electroretinography (mfERG). *Doc Ophthalmol*, 2003. 106: 105-115.

30. Polyak SL: The retina. University of Chicago Press, Chicago, 1941.
31. Wyszecki G, Stiles WS: Color science: concepts and methods, quantitative data and formulae. Wiley, New York, 1982.
32. Bienfang D, Coblyn JS, Liang MH, Corzillius M: Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. *J Rheumatol*, 2000. 27 (11): 2703-6.
33. Browning DJ: Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. *Am J Ophthalmol*, 2002. 133 (5): 649-56.
34. Alacron GS: How frequently and how soon should we screen our patients for the presence of antimalarial retinopathy? *Arthritis Rheum*, 2002. 46 (2): 561.
35. Easterbrook M: Hydroxychloroquine retinopathy. *Ophthalmology*, 2001. 108 (12): 2158-9.
36. Coyle JT: Hydroxychloroquine retinopathy. *Ophthalmology*, 2001. 108 (2): 243-4.
37. Warner AE: Early hydroxychloroquine macular toxicity. *Arthritis Rheum*, 2001. 44 (8): 1959-61.
38. Shroyer NF, Lewis RA, Lupski JR: Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? *Am J Ophthalmol*, 2001. 131 (6): 761-6.
39. Mazzuca SA, Young R, Brandt KD, Yee RD, Katz BP: Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. *J Rheumatol*, 1994. 21: 59-63.

40. Koehler B: Antimalarial workshop. *J Rheumatol*, 1997. 24: 1393-5.
41. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines.. Guidelines for monitoring drug therapy in rheumatoid arthritis. *Arthritis Rheum*, 1996. 39: 723-7.
42. Easterbrook M, Bernstein H. Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns. *J Rheumatol*, 1997. 24: 1390-2.
43. Morsman CDG, Livesey SJ, Richards IM, Jessop JD, Mills PV: Screening for hydroxychloroquine retinal toxicity: is it necessary? *Eye*, 1990. 4: 572-6.
44. Berstein H: Ocular safety of hydroxychloroquine sulfate (Plaquenil). *South Med*, 1992. 85: 274-9.
45. Falcon PM, Paolini L, Lou PL: Hydroxychloroquine toxicity despite normal dose therapy. *Ann Ophthalmol*, 1993. 25: 385-8.
46. Bernstein HN: Ocular safety of hydroxychloroquine. *Ann Ophthalmol*, 1991. 23: 292-6.
47. Easterbrook M: Detection and prevention of maculopathy associated with antimalarial agents. *Int Ophthalmol Clin*, 1999. 39: 49-57.
48. Spalton DJ, Verdon Roe GM, Hughes GRV: Hydroxychloroquine, dosage parameters and retinopathy. *Lupus*, 1992. 2: 355-8.
49. Blythe C, Lane C: Hydroxychloroquine retinopathy: is screening necessary? *BMJ*, 1998. 316: 716-7.
50. Block JA: Hydroxychloroquine and retinal safety. *Lancet*, 1998. 351: 771.

51. Bernstein NH: Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. *Am J Med*, 1983. 75: 25-34.
52. Suchard RA: Validity and interpretation of Amsler grid reports. *Arch Ophthalmol*, 1993. 111: 776-80.
53. Vu BL, Easterbrook M, Hovis JK: Detection of color vision defects in chloroquine retinopathy. *Ophthalmology*, 1999. 106 (9): 1799-803.
54. Herman K, Leys A, Spileers W: (Hydroxy)-chloroquine retinal toxicity: two case reports and safety guidelines. *Bull Soc Belge Ophthalmol*, 2002. 284: 21-9.
55. Dowling JE, Boycott BB: Organization of the primate retina: electron microscopy. *Proc R Soc Lond Biol Sci*, 1966. 166: 80-111.